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Highlights 
 Flualprazolam was frequently detected in fatalities in Sweden and Finland 
 Flualprazolam was implicated in the cause of death in 40% of the studied cases 
 Flualprazolam was the only intoxicant found in two (6%) poisoning cases 




Flualprazolam is a novel designer benzodiazepine, structurally related to alprazolam, 
flubromazolam and triazolam. In the last couple of years, it has been frequently detected in 
seizures and in forensic cases in Sweden and Finland. However, there is a lack of published 
blood concentrations for the drug, which presents difficulties when assessing its relevance for 
the cause of death. 
A quantitative method for the determination of flualprazolam in post-mortem blood was 
developed and validated, and subsequently used to analyse samples from 33 deaths 
previously screened as testing positive for flualprazolam in Sweden and Finland. 
Most of the cases in the study were accidental deaths (61%) or suicides (18%). The median 
(range) flualprazolam concentration was 18.0 (3.0–68) ng/g. The majority of the deceased 
were male (82%) and the median age was 30 years. The median age in the Swedish cases was 
significantly higher (35 years) than in the Finnish cases (23 years) (p < 0.05). Poly-drug use 
and particularly the concomitant use of flualprazolam and opioids were very common in the 
study population. Most of the cases that were positive for flualprazolam were fatal poisonings 
by a drug (N = 23), and in 13 cases, flualprazolam was implicated in the cause of death.  
Combining the resources of two countries in which all post-mortem toxicology is centralised 
provided a more comprehensive insight into the toxicology of flualprazolam. Research on 
novel psychoactive substances, such as flualprazolam, is required in order to be able to 







The new psychoactive substance flualprazolam is a designer benzodiazepine formally notified 
by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) on behalf of 
Sweden in February 2018, and it was also identified by German researchers in samples from 
controlled purchases in late 2017 [1,2]. 
In Sweden, flualprazolam was first seized by the police in November 2017 and in Finland by 
customs in February 2018. Since then, flualprazolam has been detected in over 500 seizures 
(predominantly in Sweden), mainly in the form of tablets. 
Flualprazolam is the ortho-fluoro analogue of alprazolam and is also structurally related to 
triazolam and flubromazolam (as seen in figure 1). Flualprazolam was first described in a 
patent filed by the Upjohn Company in 1969 [3] where it was shown to have similar potency 
to triazolam and be more potent than alprazolam in a number of tests on mice models. These 
results were further explored by Hester et al. [4] by additional tests in mice models. The 
results indicate that flualprazolam adds to the sedative effect of ethanol and pentobarbital at 
concentrations similar to those of alprazolam and approximately at an order of magnitude 
lower than those of diazepam. The high potency is also reported by user communities with 
Tripsit [5] who reported common doses of 0.2 to 0.5 mg (alprazolam 0.5–1.5 mg). 
The metabolism of flualprazolam was investigated using human liver microsomes by Wilde et 
al. [1], who reported hydroxylations at either the α-position of the triazolo ring or the 4-
position of the diazepine ring (as shown in figure 1). 
Mei et al. [6] developed a liquid chromatography tandem mass spectrometry (LC-MS/MS) 
method to measure 13 different designer benzodiazepines in post-mortem blood after solid 
phase extraction. In one sample, 1.9 ng/mL in femoral blood was reported without case 
details. To the best of our knowledge this is the only information available on flualprazolam 
concentrations in blood, limiting the ability to interpret suspected flualprazolam intoxications 
as well as to identify appropriate limits of quantification for screening and confirmation 
assays. 
Flualprazolam is topical in Sweden and Finland as a substantial number of post-mortem cases 
testing positive for this drug have been found within a short period of time. The aims of this 
study were to develop and validate a quantitative method for flualprazolam in blood by using 
a gas-chromatography negative-chemical-ionization mass spectrometry (GC-NCI-MS) method 
modified for the purpose from the work Gunnar et al. in 2006 [7], and to use the method to 
quantify flualprazolam in the post-mortem cases from both Sweden and Finland, relating the 
results to the case findings. 
 
Material and methods 
Flualprazolam was included in the GC-NCI-MS method for the quantitative screening of 
benzodiazepine drugs and metabolites. Alprazolam-d5 was used as an internal standard for 
flualprazolam. Neither flualprazolam nor alprazolam-d5 form silyl derivatives in the sample 
preparation process.   
Chemicals and materials 
Flualprazolam 1.0 mg/mL in methanol was purchased from Chiron AS, Trondheim, Norway. 
Diazepam-d5 1.0 mg/mL, nordiazepam-d5 1.0 mg/mL, temazepam-d5 1.0 mg/mL, oxazepam-
d5 1.0 mg/mL, clonazepam-d4 100 ng/mL and alprazolam-d5 100 ng/mL in methanol were 
from Cerilliant, Round Rock, Texas, USA. N-Methyl-N-tert-
butyldimethylsilyltrifluoroacetamide (MTBSTFA) with 1% tert-butyldimethylchlorosilane 
(TBDMSCl) was from Sigma-Aldrich, Steinheim, Germany. 
The extraction solvent contained 0.50 ng/mL each of diazepam-d5, nordiazepam-d5, 
temazepam-d5 and oxazepam-d5, and 0.10 ng/mL each of clonazepam-d4 and alprazolam-d5 
in butyl acetate. 
Calibration and validation experiments were carried out using lamb’s blood fortified with 1% 
sodium fluoride (NaF). 
Sample preparation 
The blood sample (0.5 g) was transferred into a 6 mL centrifuge tube, 0.5 ml of 0.5 M Na2HPO4 
buffer solution (pH 9) was added, and the tube was mixed for five seconds in a vortex mixer. 
The extraction solvent (0.5 mL) was added, and the tube was mixed for 30 seconds in a vortex 
mixer. After centrifuging (5 min, 4330 g), the organic layer (50 µL) was transferred into a 
conical-bottomed autosampler vial and evaporated to dryness under a gentle steam of 
nitrogen (85°C, 30–45 s). Butyl acetate (50 µL) and MTBSTFA with 1% TBDMSCl (10 µL) 
were added, and the vial was capped and heated at 85°C for 30 minutes. 
Gas chromatography–mass spectrometry  
GC-NCI-MS was performed with a 7977A mass selective detector coupled to a 7890B gas 
chromatograph, equipped with a 7693 injector (Agilent Technologies, Santa Clara, CA, USA) 
and a ZB-DRUG-1 (15 m x 0.25 mm, 0.25 µm) capillary column (Phenomenex, Torrance, CA, 
USA). GC-NCI-MS was operated with MassHunter software. Gas chromatography (GC) was 
used in the splitless and constant flow mode using a 1 µL injection volume and a column flow 
rate of 2.5 mL of helium 5.6 (99.9996%) per minute. The injector temperature was 250°C and 
the transfer line temperature was 300°C. The oven temperature was initially held at 160°C for 
1 min and then increased by 50°C per min to 320°C, which was then held for 2 min. The NCI 
mode was used with methane 5.5 (99.9995%) as a reagent gas. The flow controller was set at 
40%. The quadrupole and ion source temperatures were 150°C. GC-NCI-MS analysis was 
performed by selected ion monitoring (SIM) with dwell time of 10 ms, using the ions m/z 326 
and 328 for flualprazolam and m/z 313 and 315 for alprazolam-d5.  The runtime of the 
analysis was 6.2 minutes, and the retention times for flualprazolam and alprazolam-d5 4.626 
min and 4.788 min, respectively. 
Validation  
The working range of the method was studied by constructing calibration curves in blood 
(table 1). Quadratic calibration models were chosen with 1/x weighting (5, 10, 20, 50 and 125 
ng/g with flualprazolam concentration ≥ 5.0 ng/g and 2, 3, 4, 5, 10 and 20 ng/g with 
flualprazolam concentration < 5.0 ng/g). The following correlation coefficient values were 
obtained: R2 = 0.999932 for 5–125 ng/g and R2 = 0.998988 for 2–20 ng/g. 
The acceptance criteria for the working range were 15% relative standard deviation (RSD) for 
imprecision and ±15% for bias using five replicates at each calibration point. The signal-to-
noise ratio (S/N) at the limit of detection (LOD) was S/N > 3. 
Table 1. Validation data for flualprazolam in blood  































*N = 14 during a four-week period with calibration model 5–125 ng/g 
Post-mortem cases 
The subjects were autopsied in Sweden or Finland in connection with medico-legal cause-of-
death investigations. Femoral venous blood was collected at autopsy in plastic tubes with 
≈1% NaF and stored at +4°C. The study included all cases that were previously proven to be 
positive for flualprazolam by following standard qualitative drug screening procedures for 
blood or urine samples during the period from June 2018 to July 2019 in Finland and from 
February 2018 to January 2019 in Sweden. 
The regional ethics committee in Linköping approved the inclusion of the Swedish cases 
(2018–186/31). According to the Finnish guidelines, no ethics approval was necessary for the 
Finnish part of the study. 
Statistical analysis 
All statistical analyses were carried out using IBM SPSS software (version 25). As the 
frequency distributions of the blood concentrations and the age of the deceased were skewed, 
medians were used to characterise the data. The analysis was performed using the Mann–
Whitney U test for independent samples. A p value <0.05 was regarded as statistically 
significant. 
Results 
The post-mortem cases that tested positive for flualprazolam in the initial drug screening 
were analysed using the developed GC-NCI-MS method. The limit of quantification was 
exceeded by 23 samples from Sweden and 10 from Finland. The flualprazolam blood 
concentration in each of the cases, the cause and manner of death, and the other relevant 
findings are given in table 2.  
The median (range) concentration in all of the studied cases was 18.0 (3.0–68) ng/g. The 
median flualprazolam concentration was somewhat lower in the Swedish cases (17.0 ng/g) 
than in the Finnish cases (22.5 ng/g), but the difference was not statistically significant (p > 
0.05). The median concentration in cases where flualprazolam was implicated in a fatal 
poisoning was 19.0 ng/g, which is not significantly different from that in the whole study 
population (p > 0.05). 
The median (range) age of the deceased was 30 (16–70) years. The median age in the 
Swedish cases was significantly higher (35 years) than in the Finnish cases (23 years) (p < 
0.05). The median age in fatal flualprazolam poisonings (n = 13) was 28 years. 
Of the deceased that tested positive for flualprazolam, 27 (82%) were male and 6 (18%) were 
female. The median age of women (25 years) was lower than that of males (31 years), but the 
difference was not statistically significant (p > 0.05). 
In 23 (70%) of the cases, the cause of death was fatal poisoning by a substance and in 13 cases 
(40%) flualprazolam was one of the substances implicated in the fatal poisoning. Cases 
testing positive for flualprazolam were determined to be fatal poisonings more often in 
Finland than in Sweden (80% in Finland vs 35% in Sweden), and the drug was also implicated 
more often in Finland (50% in Finland vs 35% in Sweden). In two poisoning cases, 
flualprazolam was the only intoxicant reported in the cause of death. In these cases, the 
concentration of flualprazolam was 19 and 21 ng/g, respectively. One of the cases (19 ng/g) 
was stated to be an accident. Both cases were from Sweden. In the poly-drug poisoning cases, 
opioids, alcohol, pregabalin, and anti-depressants were the drugs most commonly implicated 
along with flualprazolam. 
The most common manner of death in the cases testing positive for flualprazolam was death 
by accident (n = 19, 61%), followed by suicide (n = 6, 18%), natural death (n = 4, 12%) and 
an undetermined manner of death (n = 3, 9%). In one case the manner of death was not 
reported. Three of the suicides were fatal poisonings and three were violent suicides. 
Buprenorphine was the most common other finding in cases testing positive for flualprazolam 
(n = 10), followed by medicinal opioids other than buprenorphine (n = 5), alcohol (n = 5), 
pregabalin/gabapentin (n = 5) and illegal drugs, such as amphetamine or heroin/morphine 





We present here the results of a bilateral co-operation project between Sweden and Finland 
concerning post-mortem toxicology related to flualprazolam. Autopsy cases that were initially 
positive in the standard qualitative drug screening procedures of the laboratories were 
subjected to quantitative analysis of the flualprazolam with a validated method in order to 
produce reference data for future consideration in flualprazolam-positive cases.  
The study period was approximately one year (within 2018–2019) in each country, although 
the exact time differed slightly between the countries. Sweden presented a larger number of 
cases but the number of flualprazolam poisonings was closer (8 in Sweden, 5 in Finland).  
Since there are no previous data on flualprazolam concentrations in clinical or post-mortem 
cases available, we compared the concentrations in our study to those reported for 
alprazolam and flubromazolam – two structural relatives of flualprazolam with generally low 
reported reference concentrations. The concentrations of flualprazolam in our study material 
(median 18.0 ng/g) were quite low when compared to the post-mortem concentrations of 
alprazolam in compilations available in the scientific literature, which is well in line with the 
initial information provided by the pharma industry in the 1970s about flualprazolam being 
more potent than alprazolam [3,4]. The scientific literature reports median alprazolam 
concentrations of 24 ng/g (n = 12) [8] or 50 ng/g (n = 51) [9] when the drug was considered 
unrelated to the cause of death, 16 ng/g (n = 67) [9] in fatal poisonings caused by alprazolam 
in combination with other drugs and 33 ng/mL (n = 2234) [10] when all causes of death were 
taken into account. The post-mortem concentrations reported for flubromazolam in femoral 
blood in two fatal methadone intoxication cases were lower than the median flualprazolam 
concentration in our cases – 8.0 and 4.4 ng/g [11]. In a third case, flubromazolam 
concentration in heart blood was 40 ng/mL (cause of death not reported) [6]. However, the 
number of reported flubromazolam found in the literature is too low for meaningful 
comparison. 
The high potency is especially problematic in cases where flualprazolam is sold in fake 
alprazolam products, as has been reported by drug-checking services [12]. Adverse effects 
may occur if flualprazolam is mistaken for alprazolam and abused in similar doses. 
The deceased testing positive for flualprazolam in Finland were all below 40 years whereas in 
the Swedish material, eight cases were over 40 years and the oldest as much as 70 years.  
Except for the one individual aged 70 years, all the suicide victims in our material were 30 
years or younger (median: 23 years). Of the women in our study, 50% had committed suicide 
whereas the percentage for men was 11%, which is well in line with previous research 
suggesting that women with substance abuse problems are more susceptible to committing 
suicide than men with similar problems [13]. 
Only in two cases was flualprazolam the only drug detected and implicated in the cause of 
death. The concentrations in these cases (19 and 21 ng/g) were close to the median 
concentration of all the cases. In some cases with high flualprazolam concentrations in our 
material, the drug was not implicated even when the cause of death was fatal drug poisoning. 
It can be speculated whether in these cases the potency of the drug was sufficiently 
acknowledged by the forensic pathologist who determined the cause of death. This is, 
understandably, a common situation with new drugs that lack post-mortem reference values. 
 
Conclusion 
Both in Sweden and Finland, a considerable number of post-mortem cases were found to test 
positive for the previously quite unfamiliar benzodiazepine flualprazolam. The lack of 
previous data on the drug concentrations and toxicity presented a challenge when the 
relevance of the drug needed to be assessed in case work. Interestingly, differences existed 
between the two countries in terms of flualprazolam blood concentrations and particularly in 
the age of the deceased. These findings emphasise the necessity of collecting data from 
multiple areas in order to obtain a consistent toxicology profile for a new illicit drug. 
 




Cause of death Manner of 
death 
Other relevant findings (µg/g in femoral 
blood, unless stated otherwise) 
S1 4.2 Fatal poisoning by flualprazolam, 
venlafaxine and pregabalin 
Accident Venlafaxine (1.3), O-desmethyl venlafaxine 
(0.45), pregabalin (16) 
S2 18 Fatal poisoning by methadone 
and flualprazolam 
Accident Methadone (0.15) 
S3 9.7 Fatal poisoning by alimemazine Accident Alimemazine (5.0), desmethyl alimemazine 
(1.3) 
S4 17 Fatal poisoning by 
buprenorphine, flualprazolam 
and ethanol 
Accident Ethanol (0.67 ‰, in urine: 1.33 ‰), 
buprenorphine (2.8 ng/g, 0.09 µg/ml urine) 
S5 33 Ischemic cardiomyopathy caused 
by flualprazolam and N-ethyl-3-
fluoroamphetamine intake 
Accident N-ethyl-3-fluoroamphetamine (present), 3-
fluoroamphetamine (present) 
S6 28 Fatal poisoning by flualprazolam, 
mirtazapine and venlafaxine 
Suicide Mirtazapine (0.20), desmethyl mirtazapine 
(0.10), venlafaxine (0.52), O-desmethyl 
venlafaxine (0.83) 
S7 19 Fatal poisoning by flualprazolam Accident - 
S8 20 Fatal poisoning by carbon 
monoxide 
Suicide COHb (76%) 
S9 23 Bronchopneumonia Natural - 
S10 3 Brain injury due to trauma from 
falling 
Unclear - 
S11 5 Coronary arteriosclerosis Natural - 
S12 45 Fatal poisoning by heroin 
together with buprenorphine and 
pregabalin 
Accident Morphine (0.34), 6-monoacetyl morphine 
(0.006), codein (0.03), buprenorphine (2.6 
ng/g, 0.19 µg/ml urine), norbuprenorphine 
(3.9 ng/g, 0.09 µg/ml urine), pregabalin (21) 
S13 7.8 Drug -related death Not 
reported 
Amphetamine (1.7), MDMA (1.7), MDA 
(0.08), oxycodone (0.1), morphine (0.04) 
S14 20 Fatal poisoning by buprenorphine Accident Buprenorphine (0.8 ng/g, 0.09 µg/ml urine)  
S15 16 Bronchopneumonia Natural – 
S16 14 Fatal poisoning by loperamide 
and flualprazolam 
Accident Loperamide (0.06) 
S17 7.6 Fatal poisoning by tramadol Unclear Tramadol (8.5), O-desmethyl tramadol (0.43) 
S18 13 Fatal poisoning by loperamide Accident Loperamide (0.17) 
S19 21 Fatal poisoning by flualprazolam Unclear - 
S20 20 Myocardial infarction Natural - 
S21 11 Fatal poisoning by buprenorphine 
and flualprazolam  
Accident Buprenorphine (0.9 ng/g, 0.04 µg/ml urine), 
norbuprenorphine (0.2 ng/g) 
S22 36 Fatal poisoning by buprenorphine 
and alimemazine 
Accident Buprenorphine (9.0 ng/g, 0.23 µg/ml urine), 
norbuprenorphine (31 ng/g, >1 µg/ml 
urine), alimemazine (1.9), desmethyl 
alimemazine (1.8) 






Cause of death Manner of 
death 
 
F1 68 Fatal poisoning by flualprazolam, 
buprenorphine and alcohol  
Suicide Ethanol (0.40 ‰), buprenorphine (0.94 ng/g, 
17 ng/g urine), norbuprenorphine (0.83 
ng/g, 15 ng/g urine)  
F2 6.6 Fatal poisoning by tramadol and 
pregabalin 
Accident Tramadol (4), O-desmethyl tramadol (0.56), 
pregabalin (6.5) 
F3 24 Fatal poisoning by amphetamine Accident Amphetamine (0.80) 
F4 36 Fatal poisoning by 
buprenorphine, flualprazolam 
and pregabalin 
Accident Buprenorphine (120 ng/g urine), 
norbuprenorphine (7.4 ng/g urine), 
pregabalin 1.7 
F5 21 Hanging Suicide - 
F6 8.6 Crushing injuries Suicide - 
F7 30 Fatal poisoning by 
buprenorphine, flualprazolam, 
alcohol and amphetamines 
Accident Ethanol (0.68 ‰), 3-fluoroamphetamine 
(0.01), amphetamine (1.0), 
methamphetamine (0.19), buprenorphine 
(1.1 ng/g, 200 ng/g urine), 
norbuprenorphine (0.66 ng/g, >200 ng/g 
urine) 
F8 32 Fatal poisoning by 
buprenorphine, flualprazolam 
and gabapentin 
Accident Buprenorphine (8.9 ng/g, >200 ng/g urine) 
norbuprenorphine (6.8 ng/g, 200 ng/g 
urine), gabapentin (5.6) 
F9 11 Fatal poisoning by 
buprenorphine, clonazepam and 
THC 
Accident Buprenorphine (0.51 ng/g, 110 ng/g urine), 
norbupruprenorphine (14 ng/g urine), 7-
aminoclonazepam (0.040) 
F10 13 Fatal poisoning by flualprazolam 
and alcohol 
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